Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
about
Does accumulation of advanced glycation end products contribute to the aging phenotype?An invertebrate hyperglycemic model for the identification of anti-diabetic drugsPotential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy.Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusionSerum carboxymethyllysine, an advanced glycation end product, and age-related macular degeneration: the Age, Gene/Environment Susceptibility-Reykjavik StudySerum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetesKIOM-79 protects AGE-induced retinal pericyte apoptosis via inhibition of NF-kappaB activation in vitro and in vivoHigher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adultsAdvanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man.Litsea japonica extract inhibits neuronal apoptosis and the accumulation of advanced glycation end products in the diabetic mouse retina.Serum carboxymethyl-lysine, an advanced glycation end product, is associated with arterial stiffness in older adults.RAGE and AGEs in Mild Cognitive Impairment of Diabetic Patients: A Cross-Sectional Study.Role of advanced glycation end products in cardiovascular disease.Glycation products as markers and predictors of the progression of diabetic complications.Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more?Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of AgingAGE restriction in diabetes mellitus: a paradigm shift.N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.The Extract of Aster Koraiensis Prevents Retinal Pericyte Apoptosis in Diabetic Rats and Its Active Compound, Chlorogenic Acid Inhibits AGE Formation and AGE/RAGE Interaction.Decreased circulatory response to hypovolemic stress in young women with type 1 diabetes.DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes.Advanced glycation end products, oxidative stress and diabetic nephropathy.Naturally occurring inhibitors against the formation of advanced glycation end-products.Therapeutic potential of targeting lipid aldehydes and lipoxidation end-products in the treatment of ocular disease.Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN)Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions.Cell hypertrophy and MEK/ERK phosphorylation are regulated by glyceraldehyde-derived AGEs in cardiomyocyte H9c2 cells.Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs.Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?Glyceraldehyde-Derived Advanced Glycation End Products Accumulate Faster Than Nε-(Carboxymethyl) Lysine.Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation.Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.Update on Mechanisms of Renal Tubule Injury Caused by Advanced Glycation End Products.Clinical efficacy of 'Spleen-kidney-care' Yiqi Huayu and Jiangzhuo traditional Chinese medicine for the treatment of patients with diabetic nephropathy.High-density lipoprotein impedes glycation of low-density lipoprotein.Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neurons.Plasma low-molecular weight fluorescence in type 1 diabetes mellitus.Aster koraiensis extract prevents diabetes-induced retinal vascular dysfunction in spontaneously diabetic Torii rats.
P2860
Q24632710-3B41B375-8EF9-4EA8-A0AF-AB0A6321D498Q28477568-3A9D4EA1-530F-4EAB-AB23-90EED22EBE9BQ33772238-24D5F7A6-9ABB-400A-BCC4-7D45BCB771C3Q33789513-040CD6D4-3387-4CCC-A0A1-E162E19FE5BBQ34213760-8AEC688A-C38F-4C8C-86C0-12C850AEDAB7Q34256592-3BAE0708-BD2C-451E-A322-65A5DE4BCE3EQ34391717-B7D42063-62E5-48DE-B4C2-143D113BFE6CQ34507243-E87A33BC-F64B-47ED-925D-DEEA7D69B2E5Q35173430-7AE1D8FE-F841-4E10-96F5-FE67D4959DAEQ35237455-5883EB0A-DCD4-4A62-8365-6B360129429DQ35628566-C5A116A1-BACF-4D68-AD6E-FD1512E1CCF8Q35690158-7946CC8F-7AB7-4E9D-8268-020C06F71B5DQ35888805-0C9500EB-1D2D-498F-A709-55C30BA72711Q35929112-3A4A903B-1E68-43CB-8B3A-83D5D823C2C8Q36203971-4E822E05-61C3-47F4-BD4E-957606BD9602Q36203996-A8554318-A7F2-496E-84C3-1B8BD4E80D9CQ36204022-C3CCECC9-E407-4101-B5A0-0AF48FBDF06AQ36212513-13968B9E-5880-4C70-865A-A28463A93F07Q37003623-25CE1651-C0DA-42F0-A21A-29C593275273Q37036184-ACEF85B2-EAB8-4131-96CA-F6D602AAFB37Q37285945-2230634F-334D-4213-A8A6-B596AED08E92Q37331346-B6AFE57F-9C9C-41E9-A4F8-D940BE5BCAF4Q37694160-0F8CAA9D-4974-4ABD-98F9-8E8E8C7FBF02Q37780646-6480D37A-32A1-4197-9ECE-83601D64FB21Q37903708-E4F0F99F-6C5A-415E-8685-0FB080F64F2AQ38077549-EFD795BE-CA16-44C7-8F96-E25786DAA78DQ38698725-7967DA7B-B7D2-4262-9FCA-106D23BD7A40Q38837915-B8404B5D-C393-470C-88C5-3ECB898EE8A8Q39216600-B6352828-EC4A-4DA0-B0A7-AD8ABE2E2033Q39436295-E04BFAC8-4D55-44CC-9471-BF230FAE2285Q40802125-C89C806E-6AF4-46BB-8F74-4AB87774EDCFQ40955558-4A60A94B-1049-4D87-ABD0-594C1DC9024EQ41227936-AF82AFD8-6937-4CD2-BB07-B9202748BBDBQ41789363-537AC88D-F708-41D7-B35B-6F6746C50614Q41833272-9A562069-941E-4AD0-A4D9-DB1A10742760Q42434700-FA5DB895-991D-4FD2-AC5A-7F5D97170BBFQ44036673-B334814E-877D-4F06-A7A6-FA712FD6575EQ44455399-B7D5D6BA-F240-44B7-8DEB-763B8DE07BD7Q46613203-801D2D77-E609-4164-852B-1C78106A1C0BQ47159091-0BD21311-568A-4BFA-9EC5-8A583A430419
P2860
Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Serum levels of non-carboxymet ...... patients with Type 1 diabetes.
@en
Serum levels of non-carboxymet ...... patients with Type 1 diabetes.
@nl
type
label
Serum levels of non-carboxymet ...... patients with Type 1 diabetes.
@en
Serum levels of non-carboxymet ...... patients with Type 1 diabetes.
@nl
prefLabel
Serum levels of non-carboxymet ...... patients with Type 1 diabetes.
@en
Serum levels of non-carboxymet ...... patients with Type 1 diabetes.
@nl
P2093
P1476
Serum levels of non-carboxymet ...... patients with Type 1 diabetes.
@en
P2093
Hiroshi Yamamoto
Junnosuke Miura
Masayoshi Takeuchi
Sho ichi Yamagishi
Yasuhiko Iwamoto
Yasuko Uchigata
Zenji Makita
P356
10.1016/S1056-8727(02)00183-6
P577
2003-01-01T00:00:00Z